Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines By: The Law Offices of Vincent Wong via AccessWire October 27, 2021 at 11:45 AM EDT NEW YORK, NY / ACCESSWIRE / October 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.InnovAge Holding Inc. (NASDAQ:INNV)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/innovage-holding-inc-loss-submission-form?prid=20713&wire=1Lead Plaintiff Deadline: December 13, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.Allegations against INNV include that: (1) certain of InnovAge's facilities failed to provide covered services, provide accessible and adequate services, manage participants' medical situations, and oversee use of specialists; (2) as a result, the Company was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services; (3) as a result, there as a significant risk that CMS would suspend new enrollments pending an audit of the Company's services; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.D-MARKET Elektronik Hizmetler ve Ticaret Anonim irketi a/k/a D-MARKET Electronic Services & Trading d/b/a/ Hepsiburada (NASDAQ:HEPS)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/d-market-elektronik-hizmetler-ve-ticaret-anonim-irketi-a-k-a-d-market-electronic-services-trading-d-b-a-hepsiburada-loss-submission-form?prid=20713&wire=1Lead Plaintiff Deadline: December 20, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Hepsiburada American Depositary Receipts ("ADRs") pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's July 2021 initial public offering.Allegations against HEPS include that: (1) Hepsiburada suffered a sharp deceleration in operational and sales growth during second quarter 2021; (2) as a result, the Company initiated certain actions to fortify its competitive position, including investing in electronics and high frequency categories and discounting certain categories; (3) as a result of the foregoing, Hepsiburada's revenue and Gross Merchandise Value had declined during second quarter 2021; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=20713&wire=1Lead Plaintiff Deadline: December 22, 2021Class Period: January 13, 2020 - September 3, 2021Allegations against BMRN include that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.comSOURCE: The Law Offices of Vincent WongView source version on accesswire.com: https://www.accesswire.com/669924/SHAREHOLDER-ALERT-INNV-HEPS-BMRN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines By: The Law Offices of Vincent Wong via AccessWire October 27, 2021 at 11:45 AM EDT NEW YORK, NY / ACCESSWIRE / October 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.InnovAge Holding Inc. (NASDAQ:INNV)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/innovage-holding-inc-loss-submission-form?prid=20713&wire=1Lead Plaintiff Deadline: December 13, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.Allegations against INNV include that: (1) certain of InnovAge's facilities failed to provide covered services, provide accessible and adequate services, manage participants' medical situations, and oversee use of specialists; (2) as a result, the Company was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services; (3) as a result, there as a significant risk that CMS would suspend new enrollments pending an audit of the Company's services; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.D-MARKET Elektronik Hizmetler ve Ticaret Anonim irketi a/k/a D-MARKET Electronic Services & Trading d/b/a/ Hepsiburada (NASDAQ:HEPS)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/d-market-elektronik-hizmetler-ve-ticaret-anonim-irketi-a-k-a-d-market-electronic-services-trading-d-b-a-hepsiburada-loss-submission-form?prid=20713&wire=1Lead Plaintiff Deadline: December 20, 2021This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Hepsiburada American Depositary Receipts ("ADRs") pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's July 2021 initial public offering.Allegations against HEPS include that: (1) Hepsiburada suffered a sharp deceleration in operational and sales growth during second quarter 2021; (2) as a result, the Company initiated certain actions to fortify its competitive position, including investing in electronics and high frequency categories and discounting certain categories; (3) as a result of the foregoing, Hepsiburada's revenue and Gross Merchandise Value had declined during second quarter 2021; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=20713&wire=1Lead Plaintiff Deadline: December 22, 2021Class Period: January 13, 2020 - September 3, 2021Allegations against BMRN include that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.comSOURCE: The Law Offices of Vincent WongView source version on accesswire.com: https://www.accesswire.com/669924/SHAREHOLDER-ALERT-INNV-HEPS-BMRN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines